Previous 10 | Next 10 |
Immunic (NASDAQ: IMUX ) is up 16.2% after hours - rebounding from a regular-session decline of 5.7% - after Piper Sandler named it one of its best ideas for biotech "bargain shopping." More news on: Immunic, Inc., Lumos Pharma, Inc., Amarin Corporation plc, Healthcare stocks news, News...
Amarin-Supported Research and Analyses from Academic Collaborators to Be Featured in Five Presentations, Including Late-Breaking Science Presentation of Final EVAPORATE Study Results DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN...
Amarin Corporation's ( AMRN ) flagship product, Vascepa, is not an antiviral, steroid, antibody, or vaccine, but investors need to be aware of its potential to be a COVID-19 therapeutic. Vascepa (icosapent ethyl) is an FDA approved as an adjunct to maximally tolerated statin therapy to dimin...
Investigators at Kaiser Permanente plan to launch a study evaluating the effects of Amarin's ( AMRN +0.4% ) Vascepa (icosapent ethyl) on upper respiratory infection (URI) rates and clinical outcomes, especially involving acute viral respiratory infection from SARS-CoV-2, in adults with e...
DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced support for an investigator-initiated trial to study the effects of icosapent ethyl (VASCEPA®) (IPE) on laboratory-confirmed viral upper respiratory infec...
Amarin reports better than expected financial numbers for second quarter Amarin Corporation plc (AMRN) announced its second quarter results, and the numbers were better than anticipated. The company also provided updates about its business operations. Amarin is looking to increase the po...
Amarin (NASDAQ: AMRN) investors who had been expecting a sales explosion have instead seen the bottom fall out from under their shares, and the company's second-quarter earnings report was less than encouraging. Although the biotech's stock price has already given up 68% in 2020, management ...
Image source: The Motley Fool. Amarin (NASDAQ: AMRN) Q2 2020 Earnings Call Aug 04, 2020 , 7:30 a.m. ET Operator Continue reading
Amarin Corporation plc (AMRN) Q2 2020 Earnings Conference Call August 4, 2020 7:30 AM ET Company Participants Elisabeth Schwartz - Senior Director, Investor Relations John Thero - President and Chief Executive Officer Aaron Berg - Chief Commercial Officer Michael Kalb - Chief F...
It's been a downright miserable year for Amarin (NASDAQ: AMRN) so far. The stock imploded earlier this year after a judge invalidated key patents for hypertriglyceridemia drug Vascepa. And Amarin's shares are still down nearly 70% year to date. Investors hoped for at least a little b...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...